Company Overview and News

 
FXFLF / Fairfax Financial Holdings Ltd. 6-K (Current Report of Foreign Issuer)

2018-10-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
FXFLF

 
Damages Awarded in Lawsuit Against Exis, Adam Sender and Andrew Heller

2018-10-16 globenewswire
TORONTO, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH and FFH.U) announces that a jury verdict in its lawsuit filed in 2006 seeking damages for alleged stock market manipulation involving Fairfax shares has awarded Fairfax and its Crum & Forster subsidiary damages of US$10.9 million against Exis Capital Management and related Exis companies, Adam Sender and Andrew Heller, including punitive damages of US$3.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

2
A Familial Influence On Protective Insurance

2018-10-08 seekingalpha
Protective Insurance has changed its name, changed its executive team and is executing on a strategic plan that is delivering results.
FXFLF AVF FXFHF FAXXF FDX AIG FRFHF FRFGF FRFFF FRFZF FAXRF FRFXF 8685

19
An 8% Yield, With Record Earnings, No K-1, And Rising Rate Protection

2018-10-05 seekingalpha - 8
In mid-September, Seaspan Corp. (SSW), the world's largest independent owner, operator and manager of containerships, issued a new preferred series, Seaspan Corp., 8.00% Series I Fixed/Float Cumulative Redeemable Perpetual Preferred Shares, (SSW.PI).
FXFLF SSW FXFHF FAXXF CG FRFHF SSWN FRFGF FRFFF FRFZF FAXRF FRFXF BGK SSWA

 
Intention to Make a Normal Course Issuer Bid for Subordinate Voting Shares and Preferred Shares

2018-09-25 globenewswire
TORONTO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH)(TSX: FFH.U) announces that the Toronto Stock Exchange (the “TSX”) has accepted a notice filed by Fairfax of its intention to commence a Normal Course Issuer Bid (“NCIB”) through the facilities of the TSX (or other alternative Canadian trading systems) for its Subordinate Voting Shares and the following series of its Preferred Shares: Cumulative 5-Year Rate Reset Preferred Shares, Series C (“Series C Shares”), Cumulative Floating Rate Preferred Shares, Series D (“Series D Shares”), Cumulative 5-Year Rate Reset Preferred Shares, Series E (“Series E Shares”), Cumulative Floating Rate Preferred Shares, Series F (“Series F Shares”), Cumulative 5-Year Rate Reset Preferred Shares, Series G (“Series G Shares”), Cumulative Floating Rate Preferred Shares, Series H (“Series H Shares”), Cumulative 5-Year Rate Reset Preferred Shares, Series I (“Series I Shares”), Cumulative Floating Rate Preferred Shares, Series J (“Series J Shares”), Cumulative 5-Year Rate Reset Preferred Shares, Series K (“Series K Shares”) and Cumulative 5-Year Rate Reset Preferred Shares, Series M (“Series M Shares” and, together with the Series C Shares, Series D Shares, Series E Shares, Series F Shares, Series G Shares, Series H Shares, Series I Shares, Series J Shares and Series K Shares, the “Preferred Shares”).
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

 
Fairfax Settles Lawsuit With Morgan Keegan

2018-09-04 globenewswire
TORONTO, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH and FFH.U) announces that it has agreed, in exchange for the receipt of a payment of US$20 million, to resolve its claims against Morgan Keegan & Company, Incorporated made in its lawsuit filed in 2006 seeking damages for alleged stock market manipulation involving Fairfax shares. Fairfax continues to pursue its remaining claims against other defendants in that lawsuit, including by way of appeals against court decisions adverse to Fairfax.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

 
Railway to Churchill, Man., sold — repairs to begin 'immediately'

2018-09-01 cbc.ca
Repairs on a vital rail link to northern Manitoba are set to begin immediately, the federal government said Friday, following a deal to sell the flood-damaged line leading to the remote town of Churchill.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FRFFF

 
FXFLF / Fairfax Financial Holdings Ltd. 6-K (Current Report of Foreign Issuer)

2018-08-31 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISS
FXFLF

 
Fairfax Announces Quarterly Dividend on Series C, D, E, F, G, H, I, J, K and M Preferred Shares and Quarterly Dividend Rate for Series D, F, H and J Shares

2018-08-31 globenewswire
TORONTO, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) announces that it has declared the following quarterly dividends per share on its preferred shares:
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

15
An 8% Yield, With Big Earnings Growth, No K-1

2018-08-31 seekingalpha - 4
Seaspan Corp. (SSW) is the world's largest independent owner, operator and manager of containerships. It has an average of ~4.75 years remaining on its long-term charters, which represent 90% of its revenue. The company has had its ups and downs over the past few years and actually cut its common dividend from $.375 to $.125 in April 2017.
FXFLF SSW FXFHF FAXXF CG FRFHF SSWN FRFGF FRFFF FRFZF FAXRF FRFXF SSWA

 
Brit Selects Bottomline Technologies’ Legal Spend Management Solution

2018-08-29 globenewswire
PORTSMOUTH, N.H., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Bottomline Technologies (NASDAQ:EPAY), a leading provider of financial technology that helps make complex business payments simple, smart and secure, today announced that Brit Ltd. (Brit) has selected and implemented the Company’s Legal-X electronic billing solution to reduce costs and streamline its legal billing process.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF EPAY FRFGF FRFFF

 
Fairfax Donating US$1 Million for Kerala Flood Relief

2018-08-28 globenewswire
TORONTO, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX:FFH and FFH.U), recognizing the shattering scope of the recent floods in Kerala, India, is donating US$1 million towards relief and recovery from those floods, working primarily through the Red Cross.
FXFLF FXFHF FAXXF FRFZF FRFXF FAXRF FRFHF FRFGF FFH FRFFF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 303901508